The key to Northwest's survival has been delivering strong trial results in a tiny cadre of patients for its brain-cancer drug, called DCVax-L. A similar drug called DCVax-Direct has begun testing for a wide array of solid tumors that cannot be removed by surgery, including cancers of the colon, pancreas, breast and melanoma.
They are among an emerging new crop of drugs that coax the body's own immune system into tracking down and killing cancer cells. More specifically they harness dendritic cells, master cells of the immune system that give marching orders to its soldiers, including t-cells and b-cells, which make antibodies.
Northwest Biotherapeutics' entry into the high-stakes field follows two high-profile disappointments of dendritic cell-based therapies from ImmunoCellular Therapeutics Ltd and Dendreon Corp .
Powers, chief executive since 2011, is making the case to investors that the future of its drugs looks far different.
"If (DCVax-L) has a positive result, it could be the new standard of care for brain cancer and have potential for hundreds of millions of dollars in sales for newly diagnosed patients," said Carol Werther, a biotech analyst for Summer Street Research. "And if it works against other solid tumors, it could be a multibillion-dollar product."
Some highlight from the NWBO article out today! Immunotherapy is the future!
Sentiment: Strong Buy
Kelly, Northwest Bio (NWBO) uses your own immune system to fight the cancer, without side effects, how is it done, here you go:
First, NW Bio's DCVax uses the full set (potentially hundreds) of antigens on the patient's tumor. In contrast, the Competitor uses only six pre-selected antigens -- and actually uses only fragments (peptides) of even these six antigens. NW Bio believes that hitting the full set of antigens makes it harder for the tumor to "escape," and NW Bio has long emphasized this as a key difference between its DCVax technology and the Competitor's technology.
Second, NW Bio's DCVax uses personalized antigens from the patient's own tumor. This provides assurance that the antigen targets, which DCVax mobilizes the patient's immune system to hit, are actually on that patient's version of the cancer. In contrast, the six antigens used in the Competitor's technology are pre-selected standardized antigens that may or may not be expressed, in whole or in part, on a given patient's version of GBM brain cancer. The scientific literature has established that GBM is highly variable from patient to patient.
The patients with a new diagnosis of GBM (that were treated with DCVax-L in addition to standard care treatment) were able to survive for approximately 3 years and had a recurrence rate of 2 years. The trial showed promising results, as the survival rate was doubled and the recurrence rate was tripled in DCVax-L-vaccinated patients.
Sentiment: Strong Buy
People seem to be forgetting Ziop.....one to watch especially with its rheo- switch patented technology...can turn chemo on and off quickly similiar to oncs but with less SHOCKING results,and ziop has already had good success on early trials with brain cancer.How will that work when oncs tries to shock the brain cells....not even a mensan could figure that one out.please don't get me wrong I am invested heavily in oncs in the low 30's but much much more heavily invested in ziop due to many more possible solutions in cancer via synthetics.